Sign up USA
Proactive Investors - Run By Investors For Investors

Ventripoint Diagnostics applies for US market clearance for VMS+

The VMS+ device has already passed the ISO 60601 testing.
Heart symbol
The submission uses the existing VMS as the predicate device

VentriPoint Diagnostics Ltd (CVE:VPT) has applied to the Food and Drug Administration (FDA) for clearance for its VMS+ whole-heart analysis system to go on sale.

The medtech company has submitted a traditional 510(k) application to the FDA's Center for Devices and Radiological Health (CDRH) to request clearance for sale of the VMS+ system, which allows for analysis of all four chambers of the heart.

The submission uses the existing VMS as the predicate device and provides testing data to show that the databases for the left atrium, right atrium and left ventricle perform equally well in assessing the chamber volumes in a wide variety of heart conditions, and shapes and sizes of hearts.

The VMS+ is the first cost-effective and accurate artificial intelligence tool for measuring whole heart function using conventional ultrasound.

READ VentriPoint Diagnostics makes major stride with VMSplus receiving CE mark​

Describing the application it as a “milestone event," George Adams, the chief executive officer of Ventripoint, said: "The company is focused on making cardiac ultrasound assessments faster, easier and available to all to overcome the costs, delays and limitations of cardiac MRI." 

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

Workers at CERN
August 02 2018
Private banks and healthcare groups took part in the share placing
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use